FIGURE 3 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Ida H., Shimizu T., Nishino M., Nakamura Y., Yazaki S., Katsuya Y., Sato J., Koyama T., Iwasa S., Sudo K., Kondo S., Yonemori K., Shitara K., Shiono S., Matsuoka D., Yasuda K., Otake Y., Suzuki T., Takase T., Takashima S., Yamaguchi K., Semba T., Yamamoto N.
<p>Analyses of changes in key biomarkers from baseline to C1D8 in all dosing cohorts (<b>A</b>) and from C1D1 to C2D1 in the E7389-LF 2.1 mg/m<sup>2</sup> every-3-weeks cohort (<b>B</b>). Boxes indicate the median and quartiles, the whiskers represent the largest or smallest values within 1.5 times the interquartile range, and * denotes an unadjusted <i>P</i> value of < 0.05 (Wilcoxon signed-rank test); the diamond shape ◊ denotes outlier. Biomarkers also known as: <sup>a</sup>TEK; <sup>b</sup>CXCL10. CXCL, C-X-C motif chemokine ligand; C#, cycle; D#, day #; IP10, IFNγ-induced protein 10; Q#W, every # week; TEK, TEK receptor tyrosine kinase; TIE2, tyrosine kinase immunoglobulin and EGF homology domains 2.</p>